UK-based Clinigen, the global provider of specialist and unlicensed medicines, has entered into a collaborative agreement with Zogenix Inc, to manage a Named Patient Programme for SUMAVEL® DosePro™ (sumatriptan injection) Needle-free Delivery System.
SUMAVEL DosePro is indicated for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes. SUMAVEL DosePro provides a needle-free subcutaneous administration of sumatriptan as a potential treatment alternative to oral and nasal triptans.
Zogenix and its co-promotion partner, Astellas Pharma US, Inc., launched SUMAVEL DosePro in the United States in January 2010. The Company’s development and commercialisation partner in Europe, Desitin Arzneimittel GmbH, has secured several marketing authorisations in Europe and has launched SUMAVEL DosePro in Germany.
Clinigen will manage the Named Patient Programme and supply SUMAVEL DosePro to healthcare providers in countries where SUMAVEL DosePro is not yet registered.
Scott Smith, Chief Operating Officer of Clinigen Pharma said: “We are delighted to have been selected by Zogenix. The Clinigen team has extensive international experience of delivering and supporting Named Patient Supply programmes and we look forward to receiving and fulfilling requests for treatment.”
Roger L. Hawley, Chief Executive Officer of Zogenix, stated: “We are committed to improving patient access to SUMAVEL DosePro in a legal and ethical manner, and Clinigen is an established leader in executing named patient programmes. Our agreement provides a valuable resource for healthcare professionals and migraine patients who are unsatisfied with their current approved treatment options to access SUMAVEL DosePro on a named patient basis.”
Clinicians and Pharmacists wishing to access SUMAVEL DosePro should contact Clinigen:
T: +44 (0) 1283 494340
F: +44 (0) 1283 494341
Notes to editor
Clinigen provides global access solutions for specialist medicines and Named Patient Programmes. A UK-based company, Clinigen develops solid, flexible and effective partnerships to facilitate and address the needs of patients, healthcare professionals and biopharmaceutical companies. The Clinigen Group Companies provide services throughout the entire pharmaceutical life cycle, addressing the unmet medical needs of patients by delivering unparalleled solutions.
Zogenix, Inc. (NASDAQ: ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercialising and developing products for the treatment of central nervous system disorders and pain. Zogenix’s first commercial product, SUMAVEL® DosePro™ (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix’s lead investigational candidate, ZX002, is a novel, oral, single-entity controlled-release formulation of hydrocodone, currently in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy.
For further information, please contact:
Scott Smith, Clinigen
T: +44 (0) 1283 494 340